查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961424

浸潤性乳管癌治療市場－全球產業規模、佔有率、趨勢、機會、預測：治療方法、類型、分銷管道、地區和競爭格局分類，2021-2031年

Invasive Ductal Carcinoma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy, By Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球浸潤性乳管癌治療市場預計將從 2025 年的 86.7 億美元成長到 2031 年的 139.3 億美元，複合年成長率為 8.22%。

該市場涵蓋手術、放射治療和化學療法，旨在治療最常見的乳癌類型——起源於乳房導管並擴散至鄰近組織的乳癌。推動市場成長的關鍵因素是全球乳癌發生率的上升以及人口老化對先進腫瘤治療的需求。此外，政府推行的促進早期檢測和完善癌症治療報銷機制的措施也顯著提升了對這些治療方法的需求，確保了該市場成長不受短暫市場趨勢的影響。

市場概覽
預測期 2027-2031
市場規模：2025年 86.7億美元
市場規模：2031年 139.3億美元
複合年成長率：2026-2031年 8.22%
成長最快的細分市場 標靶治療
最大的市場 北美洲

然而，創新生物製藥和尖端標靶治療的高昂成本構成了一大障礙，可能限制其在發展中地區的市場擴張。例如，美國癌症協會估計，到2024年，美國女性將新增310,720例侵襲性乳癌病例。儘管臨床需求迫切，但昂貴的治療通訊協定所帶來的經濟障礙仍然阻礙著市場成長。

市場促進因素

全球浸潤性乳管癌發生率的上升是市場成長的主要驅動力，持續推高了全球對癌症治療的需求。作為最常見的乳癌亞型，其龐大的新病例數量迫使手術、放射治療和化學療法不斷擴展。這一日益嚴重的負擔在全球範圍內不容忽視。世界衛生組織（世衛組織）在2024年2月發布的新聞稿中指出，在其關於全球癌症負擔日益加重的報告中，乳癌是女性第二大常見癌症，2022年新增病例約230萬例。各國統計數據也反映了這一規模，凸顯了持續開發有效治療策略的必要性。例如，加拿大癌症協會預測，2024年加拿大將有30,500名女性被診斷出罹患乳癌，凸顯了已開發國家建立健全的治療體系的迫切性。

同時，標靶治療和免疫療法的快速發展正在改變市場格局，推動標準治療方案向高效且精準的治療方法轉變。製藥公司正見證著創新作用機制藥物（例如 CDK4/6 抑制劑和抗體藥物複合體(ADC)）的快速商業性應用，這些藥物與傳統化療相比，能夠顯著提高患者的生存率。這種向高品質治療方案的轉變，正為主要市場參與企業帶來可觀的收入。例如，諾華公司於 2024 年 10 月發布的 2024 年第三季中期財務報告顯示，其標靶治療藥物 Kiscal 的季度銷售額達到 7.87 億美元，年增 43%。如此強勁的財務表現表明，先進標靶治療的臨床應用是市場擴張的主要驅動力，能夠克服成熟市場中的成本障礙。

市場挑戰

新型生物製藥和先進標靶治療的高昂成本嚴重阻礙了全球浸潤性乳管癌治療市場的擴張。儘管這些藥物治療方法能夠改善侵襲性乳癌患者的臨床療效，但其高昂的價格卻造成了沉重的經濟負擔（經濟毒性）。這種經濟壓力阻礙了昂貴治療方法的廣泛應用，尤其是在醫療資源有限的中低收入國家。因此，這些地區的醫療機構往往被迫依賴療效較差、過時的治療方案，縮小了高價值藥物的潛在市場，並限制了這些地區製藥公司的商機。

此外，缺乏廣泛的保險覆蓋和公共資金支持加劇了這個問題，實際上將全球相當一部分患者排除在現代醫學之外。當患者面臨高額自付費用時，治療的連續性就會受到影響，藥物使用量往往會直接減少。世界衛生組織（世衛組織）2024年的全球調查凸顯了這種資金分配不均的現象，調查顯示，僅有39%的參與國將基礎癌症治療納入其核心醫療服務體系。這種資金支持的匱乏嚴重阻礙了市場成長，因為先進療法在浸潤性乳管癌治療中的應用很大程度上依賴於完善的報銷機制。

市場趨勢

價格親民的生物類似單株抗體的市場佔有率不斷提高，顯著改變了治療格局，減輕了傳統生物製藥帶來的經濟負擔。隨著關鍵HER2標靶治療的專利到期，醫療系統正積極轉向生物相似藥，以擴大患者用藥範圍並最大限度地提高腫瘤治療領域的經濟效益。曲妥珠單抗的這種轉變尤其顯著，其生物等效替代品已迅速取代原廠藥，並在許多地區成為標準治療方案。這種廣泛應用得益於其高滲透率；根據三星生物製劑公司於2025年5月發布的《2025年第二季度生物類似藥市場報告》，到2024年第四季度，生物相似藥已佔據曲妥珠單抗市場87%的佔有率。

同時，免疫查核點抑制劑在三陰性乳癌(TNBC) 治療中的廣泛應用，標誌著這種高侵襲性且難治性亞型癌症治療領域的突破性進展。雖然荷爾蒙受體陽性乳癌可從標靶 CDK4/6 抑制劑中獲益，但 TNBC 傳統上依賴化療。然而，將 PD-1/PD-L1 抑制劑納入輔助性治療和輔助性治療，為提高存活率開闢了新的途徑。這種向免疫療法的臨床轉變，為關鍵的查核點抑制劑帶來了顯著的商業性吸引力，即使在其他領域市場飽和的情況下，其收入仍保持成長。為了佐證這一經濟影響，默克公司於 2025 年 10 月發布的 2025 年第三季財報顯示，其旗艦免疫療法藥物 Keytruda 的季度銷售額成長了 10%，達到 81 億美元，凸顯了免疫腫瘤學領域藥物的強勁需求，該領域的適應症正在不斷擴大，涵蓋乳癌和其他癌症。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球浸潤性乳管癌治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（標靶治療、荷爾蒙療法、化療、免疫治療）
    • 類型（荷爾蒙受體陽性，HER2陽性）
    • 分銷管道（醫院藥房、零售藥房、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美浸潤性乳管癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲浸潤性乳管癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區浸潤性乳管癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲浸潤性乳管癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲浸潤性乳管癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球浸潤性乳管癌治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Pfizer Inc.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • MacroGenics, Inc.
  • Celldex Therapeutics, Inc.
  • Janssen Global Services, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25076

The Global Invasive Ductal Carcinoma Treatment Market will grow from USD 8.67 Billion in 2025 to USD 13.93 Billion by 2031 at a 8.22% CAGR. The Global Invasive Ductal Carcinoma Treatment Market involves surgical, radiation, and pharmacological therapies to address the most frequent type of breast cancer arising in milk ducts and spreading to adjacent tissues. Growth is chiefly propelled by the increasing prevalence of breast malignancies globally and an aging population necessitating enhanced oncological attention. Additionally, government efforts encouraging early detection and better reimbursement structures for cancer care substantially bolster the demand for these treatments, ensuring growth independent of temporary market fads.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.67 Billion
Market Size 2031USD 13.93 Billion
CAGR 2026-20318.22%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Nevertheless, the high prices of innovative biologics and cutting-edge targeted therapies pose a major hurdle, potentially limiting market reach in developing areas. Highlighting the magnitude of the affected demographic, the American Cancer Society estimated that 310,720 new invasive breast cancer cases would be diagnosed among US women in 2024. Although the clinical necessity is urgent, the economic obstacles linked to costly therapeutic protocols persist in hindering wider market development.

Market Driver

The increasing global occurrence of invasive ductal carcinoma serves as the primary engine for market growth, generating persistent demand for cancer treatments worldwide. As the most common breast cancer subtype, the immense number of new cases requires the continual expansion of surgical, radiation, and drug-based treatment capabilities. This escalating burden is globally apparent; the World Health Organization reported in a February 2024 press release regarding the growing global cancer burden that female breast cancer was the second most frequent cancer globally, with roughly 2.3 million new diagnoses in 2022. National statistics reflect this volume, emphasizing the ongoing need for effective care strategies; for example, the Canadian Cancer Society projected that 30,500 women in Canada would be diagnosed with breast cancer in 2024, underlining the urgent need for strong therapeutic systems in developed nations.

Simultaneously, the rapid uptake of targeted therapies and immunotherapies is transforming the market landscape by shifting the standard of care toward highly effective, precision-focused regimens. Pharmaceutical companies are witnessing swift commercial adoption of innovative mechanism-based drugs, such as CDK4/6 inhibitors and antibody-drug conjugates, which provide better survival rates than conventional chemotherapy. This transition to premium treatment options is generating substantial revenue for major industry participants. Illustrating this trajectory, Novartis's 'Q3 2024 Interim Financial Report' from October 2024 revealed that sales of its targeted therapy Kisqali hit $787 million for the quarter, a 43% year-over-year rise. Such strong financial results demonstrate that the clinical use of advanced targeted agents is a key driver of market acceleration, overcoming cost hurdles in mature markets.

Market Challenge

The exorbitant costs linked to new biologics and sophisticated targeted therapies present a major obstacle to the expansion of the Global Invasive Ductal Carcinoma Treatment Market. While these pharmacological treatments offer enhanced clinical results for patients with invasive breast cancer, their high price points induce serious financial toxicity. This economic strain limits the broad uptake of premium therapies, especially in low- and middle-income nations where healthcare resources are tight. Consequently, medical providers in these areas are often compelled to depend on outdated, less efficacious care standards, which curtails the potential market for high-value drugs and hinders revenue opportunities for manufacturers in these regions.

Furthermore, the absence of extensive insurance coverage and public funding intensifies this issue, effectively excluding a significant portion of the global patient base from modern medical care. When patients encounter steep out-of-pocket costs, adherence to treatment frequently suffers, directly lowering the quantity of therapeutics used. To underscore this funding gap, a 2024 World Health Organization global survey indicated that only 39% of participating nations included basic cancer management within their funded core health services. This scarcity of financial support severely impedes market growth, as the adoption of advanced treatments for invasive ductal carcinoma relies heavily on the presence of sufficient reimbursement structures.

Market Trends

The growing market presence of affordable biosimilar monoclonal antibodies is significantly reshaping the therapeutic landscape by mitigating the financial burden linked to older biologics. As patents for key HER2-targeted treatments expire, health systems are vigorously shifting toward biosimilars to broaden patient access and maximize oncology funding. This transition is especially distinct regarding trastuzumab, where bio-equivalent options have swiftly replaced the original brand, establishing themselves as the standard of care in many areas. This broad uptake is evidenced by high penetration rates; the 'Second Quarter 2025 Biosimilar Market Report' by Samsung Bioepis in May 2025 noted that biosimilars secured an 87% share of the trastuzumab market by the fourth quarter of 2024.

At the same time, the proliferation of immune checkpoint inhibitors for triple-negative breast cancer (TNBC) marks a pivotal advancement in treating this aggressive and challenging subtype. While hormone receptor-positive cancers benefit from targeted CDK4/6 inhibitors, TNBC has traditionally depended on chemotherapy; however, incorporating PD-1/PD-L1 inhibitors into neoadjuvant and adjuvant regimens offers new pathways for enhanced survival. This clinical shift toward immunotherapy is generating significant commercial traction for top checkpoint inhibitors, maintaining revenue expansion despite saturation in other areas. Highlighting this economic effect, Merck's 'Third Quarter 2025 Financial Results' from October 2025 reported that sales of its leading immunotherapy Keytruda increased by 10% to $8.1 billion for the quarter, emphasizing the robust demand for immuno-oncology agents in broadened indications such as breast cancer.

Key Market Players

  • Novartis AG
  • Pfizer Inc.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • MacroGenics, Inc.
  • Celldex Therapeutics, Inc.
  • Janssen Global Services, LLC

Report Scope

In this report, the Global Invasive Ductal Carcinoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Invasive Ductal Carcinoma Treatment Market, By Therapy

  • Targeted Therapy
  • Hormonal Therapy
  • Chemotherapy
  • Immunotherapy

Invasive Ductal Carcinoma Treatment Market, By Type

  • Hormone Receptor
  • HER2+

Invasive Ductal Carcinoma Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other

Invasive Ductal Carcinoma Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Invasive Ductal Carcinoma Treatment Market.

Available Customizations:

Global Invasive Ductal Carcinoma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Invasive Ductal Carcinoma Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy)
    • 5.2.2. By Type (Hormone Receptor, HER2+)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Invasive Ductal Carcinoma Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Invasive Ductal Carcinoma Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Invasive Ductal Carcinoma Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Invasive Ductal Carcinoma Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Invasive Ductal Carcinoma Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Invasive Ductal Carcinoma Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Invasive Ductal Carcinoma Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Invasive Ductal Carcinoma Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Invasive Ductal Carcinoma Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Invasive Ductal Carcinoma Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Invasive Ductal Carcinoma Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Invasive Ductal Carcinoma Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Invasive Ductal Carcinoma Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Invasive Ductal Carcinoma Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Invasive Ductal Carcinoma Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Invasive Ductal Carcinoma Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Invasive Ductal Carcinoma Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Invasive Ductal Carcinoma Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Invasive Ductal Carcinoma Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Invasive Ductal Carcinoma Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Invasive Ductal Carcinoma Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Invasive Ductal Carcinoma Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Invasive Ductal Carcinoma Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Invasive Ductal Carcinoma Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Invasive Ductal Carcinoma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Merck KGaA
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. AstraZeneca
  • 15.6. AbbVie Inc.
  • 15.7. Bristol-Myers Squibb Company
  • 15.8. MacroGenics, Inc.
  • 15.9. Celldex Therapeutics, Inc.
  • 15.10. Janssen Global Services, LLC

16. Strategic Recommendations

17. About Us & Disclaimer